Condition
RA
Total Trials
6
Recruiting
1
Active
1
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
50%
3 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 2 (1)
P 3 (2)
P 4 (1)
Trial Status
Completed4
Recruiting1
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07147959Phase 2RecruitingPrimary
PET-Based Imaging of Radiolabeled CIT-013
NCT04311567Phase 4Terminated
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease
NCT04224194Phase 3CompletedPrimary
Auto-injector Real Life Handling in Patients
NCT02240888Not ApplicableCompletedPrimary
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
NCT02057250Phase 3CompletedPrimary
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
NCT02240732Completed
Surgical Tourniquets and Cerebral Emboli
Showing all 6 trials